Sugimoto Hideki, Konno Shingo, Nomoto Nobuatsu, Nakazora Hiroshi, Murata Mayumi, Kitazono Hisao, Imamura Tomomi, Inoue Masashi, Sasaki Miyuki, Fuse Akihisa, Hagiwara Wataru, Kobayashi Mari, Fujioka Toshiki
Division of Neurology, Department of Internal Medicine, Toho University Ohashi, Tokyo, Japan.
PLoS One. 2014 Nov 19;9(11):e113766. doi: 10.1371/journal.pone.0113766. eCollection 2014.
To examine the impact of the plasma homocysteine level on the anti-atherosclerotic effects of pitavastatin treatment, we retrospectively examined 59 patients who had a history of stroke and had been prescribed pitavastatin for the treatment of dyslipidemia at the Neurology department of Toho University Ohashi Medical Center Hospital. The patients were classified into two groups according to their homocysteine levels. Carotid artery plaque progression was determined before and after pitavastatin treatment. Plasma levels of high-sensitivity C-reactive protein, platelet molecular markers, and von Willebrand factor were measured. Pitavastatin treatment had beneficial effects on the lipid profiles of these patients and slowed atherosclerosis progression. These effects were observed in both the high and low homocysteine groups. Proactive lipid intervention using pitavastatin may inhibit the progression of atherosclerosis and contribute to secondary prevention of stroke in high-risk patients. We conclude that this statin could inhibit progression at any stage of disease and should therefore be proactively administered to these patient groups, regardless of disease severity.
为了研究血浆同型半胱氨酸水平对匹伐他汀治疗抗动脉粥样硬化作用的影响，我们回顾性研究了59例有中风病史且在东邦大学大森医疗中心医院神经科因血脂异常而接受匹伐他汀治疗的患者。根据同型半胱氨酸水平将患者分为两组。在匹伐他汀治疗前后测定颈动脉斑块进展情况。检测高敏C反应蛋白、血小板分子标志物和血管性血友病因子的血浆水平。匹伐他汀治疗对这些患者的血脂谱有有益作用，并减缓了动脉粥样硬化进展。在高同型半胱氨酸组和低同型半胱氨酸组中均观察到了这些作用。使用匹伐他汀进行积极的血脂干预可能抑制动脉粥样硬化进展，并有助于高危患者的中风二级预防。我们得出结论，这种他汀类药物可在疾病的任何阶段抑制进展，因此无论疾病严重程度如何，都应积极给予这些患者群体使用。
